Home>Topics>Stocks>Affymetrix

Affymetrix AFFX

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Markman hearing today regarding Enzo Biochem patents

      Headlines

      Mon, 18 Aug 2014

      of the patents, an important event in patent litigation. The company has outstanding patent disputes with Abbott Labs, Affymetrix , Agilent, Becton Dickinson, Gen-Probe, Hologic, Ilumina, Life Technologies, Luminex, Roche and Seimens. Post your

    2. More on Affymetrix Q2 results

      Headlines

      Thu, 31 Jul 2014

      Affymetrix ( AFFX -0.5% ) Q2 results : Total Revenue: $85.4M (+7.4%); Operating Expenses: $85.7M (+4.0%); Operating Loss

    3. Affymetrix ( AFFX ): Q1 EPS of $0.01 beats by $0.01. Revenue of $77.9M misses by $2.06M. (PR)

      Headlines

      Tue, 30 Apr 2013

      Affymetrix ( AFFX ): Q1 EPS of $0.01 beats by $0.01 . Revenue of $77.9M misses by $2.06M . ( PR ) Post your comment!

    4. Affymetrix estimates revenue below Street expectations, shares fall

      Headlines

      Mon, 8 Oct 2012

      (Reuters) - Affymetrix Inc estimated third-quarter revenue that was below Wall Street expectations, as tightening academic funding worldwide reduced sales at its gene expression and eBioscience...

    5. Dropping Coverage of Affymetrix

      Commentary

      Mon, 29 Aug 2011

      We are no longer providing equity research on Affymetrix AFFX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    6. Affymetrix shares fall on weak Q2 revenue view

      Headlines

      Thu, 7 Jul 2011

      (Reuters) - Shares of Affymetrix Inc fell about 20 percent on Thursday, a day after the genetic analysis products maker reported preliminary second-quarter revenue below market expectations.

    7. New Morningstar Analyst Report - Affymetrix , Inc.

      Stock Reports

      Thu, 19 May 2011

      Affymetrix has faced pricing pressure on its consumables ..... a device in the sequencing market, Affymetrix has missed out on a high-growth research ..... manufacturing difficulties may have harmed Affymetrix 's reputation and prompted customers

    8. Affymetrix Turns Profit in 3Q

      Commentary

      Fri, 12 Nov 2010

      Affymetrix AFFX swung to profitability in the third ..... needle on our fair value estimate. Affymetrix reported $74 million in sales, 5 ..... cancer research. On the capital front, Affymetrix has continued to repurchase its convertible

    9. Revenue Drops in Affymetrix's 2Q

      Commentary

      Fri, 23 Jul 2010

      Affymetrix AFFX reported second-quarter results with revenue that came within its ..... Diagnostics to launch a colorectal cancer test. These efforts underpin Affymetrix 's efforts to focus investments on validation and diagnostic testing

    10. Affymetrix Lowers Revenue Outlook

      Commentary

      Wed, 7 Jul 2010

      Affymetrix AFFX today lowered its second-quarter revenue outlook to a range of $71 ..... decline. Lower second-quarter revenue will make it difficult for Affymetrix to achieve our full-year sales projections, and we are considering

    « Prev1234Next »
    Content Partners